Q-omics provides the consensus-scored PSMA5 profile across patient tissues and cancer cell-line models. PSMA5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PSMA5 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, PSMA5 protein abundance shows 21,941 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, HNSC, and PDAC as cancer lineages where PSMA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMA5 survival associations across molecular data types. PSMA5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMA5 RNA expression–survival associations across cancer types. High PSMA5 expression shows unfavorable associations in ACC, LIHC, LUAD, SCLC, KICH and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PSMA5 RNA expression.
This table summarizes PSMA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PSMA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMA5 shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, COAD, LUAD and LIHC. The HNSC box plot shows higher PSMA5 RNA expression in tumor versus normal tissue (log2 FC = +0.653, t-test p < 0.001).
This table shows molecular features associated with PSMA5 in patient tissues and cancer cell lines. In patient samples, PSMA5 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PSMA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
